Inflammatory Rheumatologic disorders in patients with Myelodysplastic Syndromes: A cross-sectional study
Background: The aim of this study was to determine the prevalence and characteristics of rheumatologic manifestations associated with MDS.
Methods: Eighty patients with MDS were evaluated by history and physical examination for inflammatory rheumatologic disorders from Jan 2013 to May 2014. Patients who had any signs or symptoms of rheumatologic disorders underwent evaluation by laboratory tests. Patients with and without inflammatory rheumatic disorders were compared for their characteristics.
Results: Of 80 participants with MDS, 9 (11.3%) patients were diagnosed as having rheumatic disorders. MDS patients with or without rheumatologic disorder were similar in demographic and hematologic parameters, except age which was lower in patients with rheumatologic disorders. (p=0.016). In younger patients, refractory cytopenia and refractory cytopenia with multilinage dysplasia were more prevalent.
Conclusion: The findings of this study indicate that rheumatologic manifestations may be present in MDS patients. Younger patients are more prone to the occurrence of MDS and rheumatic disorders.
Aster JC, Stone RM. Clinical manifestations and diagnosis of the myelodysplastic syndromes up to date. 2013;21.2.
Bouali F, Berrah A, Si Ahmed-Bouali D, et al. Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients). Rev Med Interne. 2005;26(10):777-83.
Muslimani A, Spiro T, Chaudhry A, et al. Secondary myelodysplastic syndrome after hydroxychloroquine therapy. Ann Hematol. 2007;86(7):531-4.
George S, Newman E. Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum 1992;21(6):345-54.
Méndez C, Vadillo JA G, Varela A H, et al. Polyarthritis associated with myelodysplastic syndromes. Rev Clin Esp. 1996;196(8):539-41.
Mekinian A, Braun T, Decaux O, et al. Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases. Medicine (Baltimore). 2014;93(1):1-10.
Nozaki Y, Nagare Y, Kinoshita K, et al. Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS. Rheumatol Int. 2008;28(5):487-90.
DAS M, Chhabra R, Hinton S. Cutaneous leukocytoclastic vasculitis and myelodysplastic syndrome with little or no evidence of associated autoimmune disorders-a case report and a brief review of the literature. Am J Med Sci. 2008;336(4):368-71.
Mobini M, Khosravi S, Khajavi M. Central Nervous System Vasculitis in a Patient with Myelodysplastic Syndrome. a case report. IJHOSCR. 2010:41-3.
Fernández-Miranda C, García-Marcilla A, Martín M, et al. Fernández-Miranda C1, García-Marcilla A, Martín M, Gil R, Vanaclocha F, Torres N, del Palacio A. Med Clin (Barc). 1994;103(14):539-42.
Knipp S, Hildebrandt B, Richter J, et al. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica. 2005;90(5):691-3.
Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma. 2003;44(4):593-604.
Nam E, Kang Y, Kang H, et al. Rheumatoid arthritis associated with myelodysplastic syndrome: a case report. J Korean Med Sci. 1999;14(3):319-22.
Richter J, Gossen P, Germing U, et al. Rationale for bone marrow examination in patients with inflammatory rheumatic diseases. Wien Klin Wochenschr. 2009;121(21-22.):690-9.
Chandran G, Ahern M, Seshadri P, et al. Rheumatic manifestations of the myelodysplastic syndromes: a comparative study. Aust N Z J Med. 1996;26(5):683-8.
Roy-Peaud F, Paccalin M, Le Moal G, et al. Association of systemic diseases and myelodysplastic syndromes. A retrospective study of 14 cases. Presse Med. 2003;32(12):538-43.
Castro M, Conn D, Su W,. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol. 1991;18(5):721-7.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.